1 / 16

Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE)

Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE). Duk -Hyun Kang, MD, PhD on behalf of The EASE Trial Investigators Asan Medical Center, Seoul, Korea. Introduction.

sugar
Download Presentation

Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Randomized Trial of Early Surgery Versus Conventional Treatment for Infective Endocarditis(EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial Investigators Asan Medical Center, Seoul, Korea

  2. Introduction • Infective endocarditis (IE) remains a serious disease that carries considerable mortality and morbidity • The role of surgery has been expanding in complicated IE • Due to lack of randomized clinical trials, the optimal timing and indications for surgical intervention to prevent systemic embolism in IE remain unclear

  3. EASE Trial Design • Designa prospective, open-label, randomized trial at 2 centers in Korea between 2006 and 2011 • PurposeTo evaluate the effect of early surgery on embolic events compared with conventional treatment in IE patients with high embolic risks

  4. Blood culture Echocardiography Primary Cohort (N=76) Definite Infective Endocarditis(N=134) Suspected Infective Endocarditis Yes Surgery (N=26) ConventionalTx N = 39 Need for urgent surgery? No No Medical Tx (N=18) Embolic Risk? Excluded (N=14) Yes Early Surgery N = 37 Primary end point: In-hopital death and clinical embolic events at 6 weeks

  5. Study Patients • All patients suspected of IE underwent blood cultures and echocardiography within 24 hrs after hospitalization Inclusion Criteria Exclusion Criteria • Age: 15-80 years • Definite left-sided native valve IE according to Duke criteria • Severe mitral or aortic valve disease • Vegetation length > 10mm • Pts with urgent indication of surgery moderate to severe CHF, heart block, annular or aortic abscess, penetrating lesions, fungal endocarditis • Pts not candidates for early surgery age > 80 yrs, coexisting major embolic stroke or poor medical status • Prosthetic valve IE • Right-sided vegetations • Small vegetations ≤ 10mm

  6. Study Procedures • All pts screened for eligibility underwent transesophageal echo and CT • Pts were randomly assigned on a 1:1 basis to early surgery or conventional treatment using an interactive web response system • In the early surgery group, surgery was performed within 48 hours of randomization • Pts in the conventional treatment group were treated according to the current guidelines

  7. End Points *embolic events: acute onset of embolism with occurrence of new lesions • Primary End PointA composite of in-hospital death and clinical embolic events* within 6 weeks from randomization • Secondary End PointThe rate of all-cause death, recurrence of IE, embolic events, repeated hospitalization at 6 month follow-up

  8. Statistical Analysis • Primary hypothesis To show the superiority of early surgery over conventional treatment with respect to primary end point • Power calculation • Assuming event rate 23% in the conventional treatment group and 3% in the early surgery group • Intended sample size: 74 pts for ≥ 80% power • Primary analysis on intention-to-treat principle

  9. Early Mitral Valve Repair

  10. Patient Characteristics (1)

  11. Patient Characteristics (2)

  12. End Point

  13. All Cause Mortality 0.3 0.2 Mortality 0.1 • Conventional Treatment • 5.1% Mortality at 6 Months • Early Surgery • 2.7% Months 0.0 • HR [95% CI] = 0.513 [0.047 – 5.662] 0 6 12 18 24 • P = 0.586 5.1% 2.7%

  14. End Point 0.3 0.2 End Point 28.2% 0.1 End Point at 6 Months Months 0.0 0 3 6 9 12 • Conventional Treatment • 28.2% • Early Surgery • 2.7% • HR [95% CI] = 0.083 [0.011 – 0.640] • P = 0.009 2.7%

  15. Conclusions • The EASE randomized trial showed that early surgery significantly reduced the primary end point of death and embolic events in IE patients with large vegetations • Additional randomized trials are needed in complicated IE

  16. Thank you for your attention

More Related